PRECEF Drug Patent Profile

Which patents cover Precef, and when can generic versions of Precef launch?

Precef is a drug marketed by Apothecon and Bristol and is included in two NDAs.

The generic ingredient in PRECEF is ceforanide. There is one drug master file entry for this compound. Additional details are available on the ceforanide profile page.

Summary for PRECEF

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	54
DailyMed Link:	PRECEF at DailyMed

US Patents and Regulatory Information for PRECEF

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apothecon	PRECEF	ceforanide	INJECTABLE;INJECTION	062579-002	Nov 26, 1984		DISCN	No	No
Bristol	PRECEF	ceforanide	INJECTABLE;INJECTION	050554-003	May 24, 1984		DISCN	No	No
Apothecon	PRECEF	ceforanide	INJECTABLE;INJECTION	062579-005	Nov 26, 1984		DISCN	No	No
Bristol	PRECEF	ceforanide	INJECTABLE;INJECTION	050554-004	May 24, 1984		DISCN	No	No

PRECEF market dynamics and financial trajectory: revenue drivers, pricing pressure, competitive risk, and IP-linked scenarios

Last updated: July 23, 2026

PRECEF revenue depends on (1) sustained differentiation in hospital and outpatient antibiotic workflows, (2) reimbursement and tender dynamics, and (3) how quickly competitive generics and “authorized” supply displace the brand once formulary access widens. The financial trajectory typically tracks adoption velocity after launch, then compresses as price competition accelerates and procurement shifts toward lowest-cost equivalents.

What is PRECEF and how does it make money in the market?

PRECEF is an antibiotic-branded product used in bacterial infection indications where clinicians seek dosing reliability and formulary coverage. Brand revenue is driven by:

• Prescribing and hospital formulary inclusion for targeted infection types.
• Acquisition channel mix: hospital purchasing tends to create bulk volume stability but with faster tender repricing.
• Outpatient channel reimbursement: higher patient volume can offset per-unit price cuts, but only if payer authorization is favorable.

How do hospitals vs retail drive PRECEF sales?

Hospital purchasing generally determines near-term revenue stability via tender contracts, negotiated discounting, and substitution rules. Retail contributes upside if payers cover the product broadly and prescribers keep defaulting to it.

Featured snippet answer: PRECEF’s revenue is most sensitive to formulary/tender access in hospitals and to reimbursement friction in outpatient prescribing.

What are the key commercial levers affecting PRECEF pricing?

Commercial price outcomes in antibiotic categories usually come down to:

• Competitive set size (number of equivalent offerings in active ingredient and dosage forms)
• Tender frequency and contract duration
• Payer rules on step therapy or prior authorization
• Wholesale acquisition cost (WAC) versus net price concessions
• Availability constraints of competing suppliers

Which companies compete with PRECEF and what substitution risks exist?

PRECEF faces substitution from:

• Interchangeable generics with the same active ingredient and dose form
• Authorized generics or license-based supply partners (if present)
• Therapeutic alternatives within the same antibiotic class (clinical substitution risk)

How quickly do antibiotics brands lose share to generics?

Share compression in established antibiotics usually accelerates when multiple generic SKUs gain broad distribution and when payers update formularies post-launch. The speed is higher when:

• The molecule has limited patent barriers for formulations or methods of use
• There are no unique delivery advantages that remain protected
• Procurement buyers can switch without clinical guardrails

What delivery formats and dosing strengths matter most?

Market impact typically varies by:

• Common dosing strengths that map to most inpatient regimens
• Fixed-dose convenience if competitors do not match
• Pack sizes aligned with hospital prescribing patterns

When does PRECEF face exclusivity loss, generic entry risk, and Paragraph IV pressure?

PRECEF’s generic risk is governed by:

• Expiration of listed Orange Book patents (drug substance, formulation, method-of-use, and manufacture)
• Any pediatric exclusivity, market exclusivity, or patent term adjustments that extend the effective barrier window
• Whether competitors file ANDAs with Paragraph IV certifications (indicating a legal challenge)

What is the typical “entry-to-revenue collapse” timeline?

For branded antibiotics, net revenue often shows a two-phase decline:

1. Pre-entry: price pressure begins as competitors advertise and wholesalers prepare supply.
2. Post-entry: revenue compresses as prescribers and procurement switch to lower-cost options.

Featured snippet answer: Once the first meaningful generic enters with broad distribution and payer acceptance, PRECEF’s price premium typically falls within the first 1 to 2 quarters, with share continuing to trend down over the following year.

What is the Orange Book status of PRECEF and how does it shape revenue protection?

The Orange Book status is the core determinant of branded lifecycle economics. A strong patent wall can slow first generic entry and reduce the number of at-risk filings. A thinner estate typically increases the probability of early ANDA entry and faster net price declines.

How many patents protect PRECEF and what do they cover?

Patent coverage that matters for commercial protection is usually split across:

• Drug substance patents (often the earliest expiry)
• Formulation patents (extend brand advantage via specific compositions or release profiles)
• Method-of-use patents (can restrict prescribing routes)
• Manufacturing process patents (less likely to block ANDA approval if not required for equivalence, but can affect settlement scope)

What patent litigation and settlement outcomes affect PRECEF’s financial trajectory?

Patent litigation outcomes influence timing and extent of competition. Settlement agreements in antibiotics commonly affect:

• Launch date of first generic
• “Design-around” permissions for follow-on filings
• Market allocation terms in some jurisdictions
• Exclusivity carve-outs for certain strengths or dosage forms

What litigation patterns usually change the revenue curve?

Revenue inflection typically occurs when:

• A settlement locks out first generic entry later than the earliest expiration date
• Or courts accelerate generic entry by narrowing patent enforceability

How strong is PRECEF’s patent estate and what’s the practical barrier to entry?

A strong practical barrier is reflected by:

• Multiple still-valid, non-expired Orange Book patents at key expiry windows
• Narrow claims that are hard to design around without sacrificing bioequivalence requirements
• Settlements that extend the effective commercial protection window

How does strength differ by formulation and strength?

Even within a single product, patent protection can differ across:

• Dosage strengths
• Specific excipients, coating, or release characteristics
• Packaging and manufacturing controls that map to specific SKUs

What FDA regulatory status factors influence PRECEF commercialization?

FDA status affects both competition and adoption. Key commercial levers include:

• Eligibility for substitution at the pharmacy level under the FDA’s Orange Book framework
• ANDA approval pace once legal barriers loosen
• Label expansions that can widen the addressable market

How do label changes change PRECEF market growth?

If PRECEF receives label expansions for more infection types or specific dosing guidance, it can:

• Increase prescriber comfort and switch rates
• Expand tender eligibility for additional protocols
• Reduce restriction under hospital antibiotic stewardship programs

What formulations are protected by PRECEF’s patent strategy?

Formulation IP can protect margins by limiting AB-rated substitution if competitors must launch different release profiles. Protected formulation categories include:

• Specific composition ratios
• Particle size or polymorph control
• Controlled-release or modified-release profiles
• Stability or dissolution characteristics
• Manufacturing process-linked formulation constraints

How does PRECEF compare with alternative antibiotics on commercial adoption and price erosion?

Antibiotics categories differ in how they are procured and substituted:

• Narrow-spectrum products face slower clinical switching but can still lose on price.
• Broad-spectrum regimens often face faster formulary substitution once equivalents are available.
• Products tied to guideline recommendations can retain higher share longer if competitors match outcomes.

Competitive benchmarking framework for PRECEF

Revenue durability is typically best predicted by:

• Time to first generic entry
• Number of approved generic SKUs at that time
• Net price discount trajectory after entry
• Hospital tender contract reset cycles

What generic entry scenarios are most likely for PRECEF?

Commercial outcomes cluster into three scenarios:

Scenario A: Slow competition (multiple patents + litigation delays)

• Generic entry happens later
• Price premium persists longer
• Revenues decline gradually rather than sharply

Scenario B: Single early entry (limited patent wall)

• First generic enters on one strength or SKU
• PRECEF loses share and net price quickly
• Follow-on generics accelerate subsequent erosion

Scenario C: Early multi-SKU entry (thin patent wall + broad filing)

• Rapid AB substitution in both hospital and retail
• Significant net price compression within a quarter or two
• Revenues trend toward class-market pricing

Featured snippet answer: PRECEF’s most likely revenue path is a sharp net price drop following first broad generic entry, followed by a slower decline as fewer SKUs remain undominated.

Key financial trajectory indicators investors and licensors track for PRECEF

Even without product-specific financial statements, the financial trajectory of an antibiotic brand is best tracked through:

• Net price per unit after generic entry milestones
• Unit share in hospital procurement and outpatient scripts
• Gross-to-net concession rate (rebates, discounts, chargebacks)
• Inventory adjustments around tender resets
• Spend on medical education and stewardship-aligned adoption

What metrics typically lead or lag revenue?

• Tender wins and formulary additions lead revenue growth.
• Net price compression lags legal milestones by 1 to 2 quarters due to contracting cycles and channel inventory.
• Unit share declines often lag entry by one quarter as prescribers and buyers ramp substitution.

Revenue exposure map: where PRECEF earns and where it risks compression

Revenue exposure concentrates in:

• Top hospitals or integrated systems with repeat tender cycles
• Regions with slower uptake of generics due to contracting inertia
• Strengths that match standardized protocols

Revenue risk concentrates in:

• Regions with aggressive public tender procurement
• Lines where pharmacy substitution is easiest
• Dosage strengths with limited patent protection

Key Takeaways

• PRECEF’s financial trajectory is primarily driven by formulary and tender access plus the timing of generic substitution after Orange Book-linked barriers weaken.
• Revenue usually holds steady early through differentiation and procurement fit, then compresses quickly once broad generic entry occurs.
• Litigation and settlement outcomes determine the length of the premium window, not just the earliest patent expiry date.
• The practical barrier to entry depends on the number and enforceability of listed patents, with formulation and method-of-use patents often deciding whether substitution is delayed or immediate.
• Investors and licensors should anchor forecasts on net price compression timing, unit share trends, and the breadth of first generic entry across strengths and dosage forms.

FAQs

1) What drives net price changes for antibiotic brands like PRECEF after generic launch?
Tender contract resets, payer reimbursement updates, and channel-level contracting and inventory timing.

2) How do settlement dates affect PRECEF’s “effective exclusivity” versus patent expiry?
Settlement can delay or narrow generic launch scope even if earlier patents expire, shifting the competition curve.

3) What matters more for PRECEF’s competition risk: patent expiration or ANDA approval timing?
Both matter, but revenue typically shifts after approval combined with distribution breadth and payer acceptance.

4) Do formulation patents usually extend antibiotic brand profits longer than drug substance patents?
Often yes, because formulation barriers can restrict easy substitution or force “design-around” launches that take longer.

5) What commercial signals predict whether PRECEF will lose market share quickly once generics enter?
Number of approved generic SKUs at entry, hospital tender substitution rules, and early net price discount trends at wholesalers and GPOs.

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. ANDA Approval Process and Patent Certification Requirements (Paragraph IV). U.S. Food and Drug Administration.
3. FDA. Drug Approval Reports: ANDA and NDA Review and Approval Information. U.S. Food and Drug Administration.